LU90284I2 - Montelukast ou un sel pharmaceutiquement acceptable de montelukast en particulier le sel de sodium de montelukast - Google Patents

Montelukast ou un sel pharmaceutiquement acceptable de montelukast en particulier le sel de sodium de montelukast

Info

Publication number: LU90284I2
Authority: LU; Luxembourg
Prior art keywords: montelukast; pharmaceutically acceptable; acceptable salt; sodium salt; salt
Prior art date: 1990-10-12

Application number

LU90284C

Other languages

English (en)

Original Assignee

Merck Frosst Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-10-12

Filing date

1998-09-02

Publication date

1998-11-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27082671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90284(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-09-02 Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc

1998-11-03 Publication of LU90284I2 publication Critical patent/LU90284I2/fr

Links

UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title 3
229960005127 montelukast Drugs 0.000 title 3
150000003839 salts Chemical class 0.000 title 1
159000000000 sodium salts Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
239000003199 leukotriene receptor blocking agent Substances 0.000 abstract 2
206010002383 Angina Pectoris Diseases 0.000 abstract 1
208000037487 Endotoxemia Diseases 0.000 abstract 1
206010018364 Glomerulonephritis Diseases 0.000 abstract 1
208000005392 Spasm Diseases 0.000 abstract 1
206010046851 Uveitis Diseases 0.000 abstract 1
230000003266 anti-allergic effect Effects 0.000 abstract 1
230000001088 anti-asthma Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
239000000924 antiasthmatic agent Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000002490 cerebral effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000001120 cytoprotective effect Effects 0.000 abstract 1
208000006454 hepatitis Diseases 0.000 abstract 1
231100000283 hepatitis Toxicity 0.000 abstract 1
150000002617 leukotrienes Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Quinoline Compounds (AREA)
Steroid Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

LU90284C 1990-10-12 1998-09-02 Montelukast ou un sel pharmaceutiquement acceptable de montelukast en particulier le sel de sodium de montelukast LU90284I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US59688790A	1990-10-12	1990-10-12
US74188891A	1991-08-08	1991-08-08

Publications (1)

Publication Number	Publication Date
LU90284I2 true LU90284I2 (fr)	1998-11-03

Family

ID=27082671

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU90284C LU90284I2 (fr)	1990-10-12	1998-09-02	Montelukast ou un sel pharmaceutiquement acceptable de montelukast en particulier le sel de sodium de montelukast

Country Status (26)

Country	Link
EP (1)	EP0480717B1 (fr)
JP (1)	JP2501385B2 (fr)
KR (1)	KR100227716B1 (fr)
CN (1)	CN1046711C (fr)
AT (1)	ATE165088T1 (fr)
CA (1)	CA2053209C (fr)
CY (1)	CY2094B1 (fr)
CZ (1)	CZ281274B6 (fr)
DE (2)	DE69129257T2 (fr)
DK (1)	DK0480717T3 (fr)
ES (1)	ES2114882T3 (fr)
FI (2)	FI104897B (fr)
HR (1)	HRP930751B1 (fr)
HU (2)	HU222344B1 (fr)
IE (1)	IE913609A1 (fr)
IL (3)	IL99726A (fr)
LU (1)	LU90284I2 (fr)
LV (1)	LV12187B (fr)
MX (1)	MX9101551A (fr)
NL (1)	NL990009I2 (fr)
NO (1)	NO914004D0 (fr)
NZ (1)	NZ240194A (fr)
PT (1)	PT99213B (fr)
SI (1)	SI9111647B (fr)
SK (1)	SK279944B6 (fr)
YU (1)	YU48742B (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5270324A (en) *	1992-04-10	1993-12-14	Merck Frosst Canada, Inc.	Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5472964A (en) *	1992-12-22	1995-12-05	Merck Frosst Canada, Inc.	Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
CA2111372C (fr) *	1992-12-22	2007-01-16	Robert N. Young	Acides heterocycliques diaryliques condenses en 5,6, antagonistes de la leucotriene
US5438141A (en) *	1993-05-21	1995-08-01	Merck Frosst Canada, Inc.	Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists
ES2080656B1 (es) *	1993-07-19	1996-10-16	Merck Frosst Canada Inc	Acidos de hidroxialquilquinolina fluorados como antagonistas del leucotrieno.
CA2130723C (fr) *	1993-09-03	2006-01-31	Wilhelm Quittmann	Methode pour l'obtention de derives de l'acide y-mercaptocarboxylique
DE4339724C1 (de) *	1993-11-22	1995-01-19	Siemens Ag	Gasarmatur
TW448160B (en) *	1993-12-28	2001-08-01	Merck & Co Inc	Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
CA2145735A1 (fr) *	1994-04-21	1995-10-22	Paul Hanselmann	Methode de preparation de 5-oxaspiro[2.4]heptan-6-one et nouveaux produits intermediaires intervenant dans le processus
US5523477A (en) *	1995-01-23	1996-06-04	Merck & Co., Inc.	Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5750539A (en) *	1995-06-07	1998-05-12	Merck Frosst Canada	Heteroaryl diol acids as leukotriene antagonists
US5714488A (en) *	1995-10-03	1998-02-03	Abbott Laboratories	Bis-heteroarylylmethoxyphenyl ketone derivatives as inhibitors of leukotriene biosynthesis
US5668150A (en) *	1996-07-26	1997-09-16	Abbott Laboratories	Non-symmetrical bis-heteroarylmethoxyphenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
FR2751969B1 (fr) *	1996-08-01	1998-12-04	Centre Nat Rech Scient	Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
US6262066B1 (en)	1998-07-27	2001-07-17	Schering Corporation	High affinity ligands for nociceptin receptor ORL-1
US6221880B1 (en)	1998-10-09	2001-04-24	Schering Corporation	Composition and method for treating allergic diseases
IT1320162B1 (it)	2000-02-09	2003-11-18	Rotta Research Lab	Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
CA2371048C (fr)	2002-02-06	2011-01-04	Delmar Chemicals Inc.	Procede de preparation d'acide 1-(mercaptomethyl)cyclopropylacetique
JP4308667B2 (ja) *	2002-02-06	2009-08-05	デルマーケミカルズインコーポレーテッド	１−（メルカプトメチル）−シクロプロパン酢酸の調製方法
AU2003209043A1 (en) *	2002-02-07	2003-09-02	Dr. Reddy's Laboratories Ltd.	Novel anhydrous amorphous forms of montelukast sodium salt
CA2528228C (fr)	2003-06-06	2011-09-20	Morepen Laboratories Limited	Une methode de preparation d'un sel sodique de montelukast sous forme amorphe
AU2004283832B2 (en) *	2003-10-10	2011-04-07	Synthon B.V.	Solid-state montelukast
EP1709001A2 (fr) *	2004-01-28	2006-10-11	Pliva Istrazivanje i Razvoj d.o.o.	Formes solides d'acide montelukast
EP1760077A1 (fr) *	2004-01-30	2007-03-07	Teva Pharmaceutical Industries Ltd.	Formes polymorphes du l'acide libre montelukast
CA2554572A1 (fr) *	2004-01-30	2005-08-18	Teva Pharmaceutical Industries Ltd.	Polymorphes d'acide sans montelukast
BRPI0506610A (pt)	2004-02-03	2007-05-02	Chemagis Ltd	montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico
EP1646612B1 (fr) *	2004-04-21	2009-07-01	Teva Pharmaceutical Industries Ltd	Procedes de preparation de sodium montelukast
US7501517B2 (en)	2004-04-30	2009-03-10	Synthon Ip, Inc.	Process for making montelukast and intermediates therefor
US7829716B2 (en)	2004-04-30	2010-11-09	Synthon Pharmaceuticals, Inc.	Process for making montelukast and intermediates therefor
WO2006008750A2 (fr)	2004-07-19	2006-01-26	Matrix Laboratories Ltd	Methyl 2-[(3s)-[3-[(2e)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoates
ATE500225T1 (de) *	2004-07-19	2011-03-15	Matrix Lab Ltd	Verfahren zur herstellung von montelukast und salzen davon
EP1781615A1 (fr)	2004-07-23	2007-05-09	Pliva Istrazivanje i Razvoj d.o.o.	Nouvelle forme de derive de benzenesulfonamide
WO2006021974A1 (fr) *	2004-08-23	2006-03-02	Morepen Laboratories Limited	Procede pour synthetiser un diol (viii), intermediaire du sodium de montelukast
PL205637B1 (pl) *	2004-10-22	2010-05-31	Inst Farmaceutyczny	Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
WO2006058545A1 (fr) *	2004-11-30	2006-06-08	Medichem, S.A.	Nouveau procede de preparation d'un antagoniste de leucotriene
WO2006131782A1 (fr) *	2005-06-07	2006-12-14	Glade Organics Private Limited	Procede de preparation de methyl-2-(3-(2-(7-chloro-2-quinolinyl-ethenyl)-phenyl)-3-oxopropyl)benzoate
CN101213177A (zh)	2005-07-05	2008-07-02	特瓦制药工业有限公司	孟鲁司特的纯化
EP1948612A2 (fr) *	2005-11-16	2008-07-30	Teva Pharmaceutical Industries Ltd	Procede de sechage de montelukast sodique par distillation azeotropique du solvant
AR057908A1 (es)	2005-11-18	2007-12-26	Synthon Bv	Proceso para preparar montelukast e intermediarios del mismo
US8178680B2 (en)	2005-12-13	2012-05-15	Msn Laboratories Limited	Process for the preparation of Montelukast and its pharmaceutically acceptable salts
US7572930B2 (en)	2006-02-02	2009-08-11	Chemagis Ltd.	Process for preparing 1-(mercaptomethyl)cyclopropaneacetic acid, a useful intermediate in the preparation of montelukast and salts thereof
WO2007096889A2 (fr)	2006-02-27	2007-08-30	Chemagis Ltd.	Procede de preparation de montelukast et de ses sels
EP2004609A2 (fr) *	2006-03-06	2008-12-24	Farmaprojects, S.A.	Procédé de préparation d'un antagoniste des leucotriènes
CN101432267A (zh)	2006-03-17	2009-05-13	斯索恩有限公司	孟鲁司特金刚烷胺盐
EP2004608B1 (fr)	2006-04-12	2011-09-14	Glade Organics Private Limited	Procédé amélioré pour la fabrication de montélukast sodique
US20060223999A1 (en) *	2006-05-10	2006-10-05	Chemagis Ltd.	Process for preparing montelukast and precursors thereof
GB0614485D0 (en) *	2006-07-21	2006-09-27	Pliva Istrazivanje I Razvoj D	Process
EP1886998A1 (fr) *	2006-08-09	2008-02-13	Esteve Quimica, S.A.	Procédés de purification du montelukast et ses sels d'amine
GB0618703D0 (en) *	2006-09-22	2006-11-01	Almac Sciences Ltd	Synthesis of leikotriene compounds
US7700776B2 (en)	2006-10-24	2010-04-20	Formosa Laboratories, Inc.	Compounds and preparation for montelukast sodium
US8115004B2 (en)	2006-11-20	2012-02-14	Msn Laboratories Limited	Process for pure montelukast sodium through pure intermediates as well as amine salts
US7271268B1 (en)	2006-12-22	2007-09-18	Formosa Laboratories Inc.	Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives
EP1958936A1 (fr) *	2007-02-14	2008-08-20	Inke, S.A.	Procédé pour l'obtention de montelukast
EP1988079A1 (fr) *	2007-04-25	2008-11-05	Lonza Ag	Processus de préparation d'alcools éthénylphényl actifs optiquement
PL205444B1 (pl)	2007-05-02	2010-04-30	Zak & Lstrok Ady Farmaceutyczn	Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
ES2320077B1 (es)	2007-07-31	2010-02-26	Moehs Iberica, S.L.	Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo.
KR101072896B1 (ko)	2007-10-09	2011-10-17	한미홀딩스 주식회사	이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
EP2053043A1 (fr)	2007-10-26	2009-04-29	Inke, S.A.	Sel cristallin de montelukast
DE102007061630B4 (de)	2007-12-20	2013-07-04	Formosa Laboratories, Inc.	Neue Verbindungen und Herstellung von Montelukast-Natrium
CN101817818B (zh) *	2008-03-06	2011-10-26	台耀化学股份有限公司	一种用于制备孟鲁司特钠的化合物
WO2009144742A2 (fr)	2008-05-26	2009-12-03	Aptuit Laurus Pvt Limited	Procédé amélioré de préparation de montélukast et de ses sels
TR200806298A2 (tr)	2008-08-22	2010-03-22	Bi̇lgi̇ç Mahmut	Farmasötik formülasyon
KR101123292B1 (ko) *	2008-09-26	2012-03-19	주식회사 엘지생명과학	몬테루카스트 나트륨염의 제조방법
WO2010064109A2 (fr)	2008-12-02	2010-06-10	Mayuka Labs Private Limited	Procédé de préparation amélioré de montélukast sodique et ses intermédiaires
WO2010107404A1 (fr)	2009-03-16	2010-09-23	Mahmut Bilgic	Combinaisons pharmaceutiques stables
EP2443134A2 (fr)	2009-06-16	2012-04-25	Schering Corporation	Nouveaux [3,2-c] hétéroaryl stéroïdes en tant qu'agonistes des récepteurs glucocorticoïdes, compositions et utilisations de ceux-ci
WO2011004298A1 (fr)	2009-07-09	2011-01-13	Alembic Limited	Montélukast à l'état hexaméthylène-diamine, et son utilisation pour l'élaboration de montélukast sodique
EP2287154A1 (fr)	2009-07-14	2011-02-23	KRKA, D.D., Novo Mesto	Synthèse efficace pour la préparation de montelukast
CN101638381B (zh)	2009-09-02	2012-08-29	鲁南制药集团股份有限公司	孟鲁司特钠中间体的合成方法
EP2486015A1 (fr)	2009-10-09	2012-08-15	DSM IP Assets B.V.	Synthèse d'un intermédiaire optiquement actif pour la préparation de montélukast
WO2011076237A1 (fr)	2009-12-23	2011-06-30	Pharmathen S.A.	Procédé amélioré pour la préparation du montelukast et de ses sels
WO2011121091A1 (fr)	2010-03-31	2011-10-06	Krka, D.D., Novo Mesto	Synthèse efficace pour la préparation de montélukast et nouvelle forme cristalline d'intermédiaires dans celle-ci
KR100990046B1 (ko) *	2010-07-30	2010-10-26	동국제약 주식회사	신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법
HUP1000425A2 (en)	2010-08-11	2012-03-28	Richter Gedeon Nyrt	Process for the production of montelukast sodium
TR201009398A2 (tr)	2010-11-11	2012-05-21	Bi̇lgi̇ç Mahmut	Fiziksel özellikleri geliştirilmiş tablet formülasyonları
TR201009394A2 (tr)	2010-11-11	2012-06-21	Bi̇lgi̇ç Mahmut	Geliştirilmiş montelukast formülasyonları.
US8471030B2 (en)	2010-12-06	2013-06-25	Orochem Technologies Inc.	Purification of montelukast using simulated moving bed
EP2502910A1 (fr)	2011-03-15	2012-09-26	Laboratorios Lesvi, S.L.	Sel de camphre sulfonique d'un intermédiaire clef du Montélukast
CN102690229B (zh) *	2011-03-23	2016-06-08	上海相辉医药科技有限公司	一种孟鲁司特钠的合成及其制备中间体
RU2605929C2 (ru) *	2011-07-26	2016-12-27	Сан Фарма Адвансед Ресёрч Компани Лтд.	Производные хинолина и хиноксалина, полезные в качестве антагонистов цистеинил-лейкотриена
WO2013077829A1 (fr)	2011-11-21	2013-05-30	Mahmut Bilgic	Granulés pharmaceutiques hydrosolubles
WO2014118796A1 (fr)	2013-01-31	2014-08-07	Melody Healthcare Pvt. Ltd.	Procédé in situ pour la préparation de montélukast sodique hautement pur
CN104109122B (zh) *	2013-04-16	2017-03-29	浙江奥翔药业股份有限公司	用于合成孟鲁司特的中间体化合物及其制备方法
CN104370810B (zh) *	2013-08-13	2016-10-05	天津汉瑞药业有限公司	孟鲁司特钠化合物
CN103554017B (zh) *	2013-10-25	2014-12-17	河北序能生物技术有限公司	一种孟鲁司特钠手性中间体的制备方法
CN103936671B (zh) *	2014-05-06	2015-10-28	启东东岳药业有限公司	孟鲁司特钠中间体的制备方法
CN105294556A (zh) *	2014-06-06	2016-02-03	上海迪赛诺化学制药有限公司	一种制备孟鲁司特酸的方法
CN105085391B (zh) *	2015-06-10	2017-08-22	广东默泰同创医药科技有限公司	用作白三烯受体拮抗剂的环丙基不饱和喹啉化合物及应用
CN105363019B (zh) *	2015-12-16	2018-04-24	新乡医学院第一附属医院	一种治疗溶血性贫血的环孢素组合物及其应用
CN108530355B (zh) *	2018-06-08	2019-09-10	福州华博立乐新材料科技有限公司	一种3-[2-(7-氯-2-喹啉基)乙烯基]苯甲醛的合成方法
CN108435257A (zh) *	2018-06-08	2018-08-24	福州华博立乐新材料科技有限公司	一种用于合成3-[2-(7-氯-2-喹啉基)乙烯基]苯甲醛的催化剂
IT201900008340A1 (it)	2019-06-07	2020-12-07	Genetic S P A	Sali di montelukast e loro composizioni farmaceutiche

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK282986A (da) *	1985-06-18	1987-02-24	Merck Frosst Canada Inc	Substitueret quinolin og farmaceutisk praeparat indeholdende en saadan forbindelse
IE59889B1 (en) *	1986-02-14	1994-04-20	Merck Frosst Canada Inc	2-substituted quinoline dioic acids
US4851409A (en) *	1986-02-14	1989-07-25	Merck Frosst Canada Inc.	2-substituted quinoline dioic acids and pharmaceutical compositions
JPS62258362A (ja) *	1986-05-02	1987-11-10	Terumo Corp	アミド誘導体およびこれを含有する５−リポキシゲナ−ゼ作用阻害剤
EP0271287A3 (fr) *	1986-12-11	1990-06-13	Merck Frosst Canada Inc.	Acides quinoléine dicarboxyliques et leurs amides
IL88433A0 (en) *	1987-11-25	1989-06-30	Merck Frosst Canada Inc	Diarylstyrylquinoline diacids and pharmaceutical compositions containing them
NZ233752A (en) *	1989-05-24	1993-05-26	Merck Frosst Canada Inc	Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof
WO1990015801A1 (fr) *	1989-06-22	1990-12-27	Pfizer Inc.	Sulfamides substitues et composes apparentes dans le traitement de l'asthme, de l'arthrite et des maladies apparentees

1991
- 1991-10-10 CA CA002053209A patent/CA2053209C/fr not_active Expired - Lifetime
- 1991-10-10 AT AT91309306T patent/ATE165088T1/de active
- 1991-10-10 EP EP91309306A patent/EP0480717B1/fr not_active Expired - Lifetime
- 1991-10-10 DE DE69129257T patent/DE69129257T2/de not_active Expired - Lifetime
- 1991-10-10 HU HU9103217A patent/HU222344B1/hu active IP Right Grant
- 1991-10-10 ES ES91309306T patent/ES2114882T3/es not_active Expired - Lifetime
- 1991-10-10 DK DK91309306T patent/DK0480717T3/da active
- 1991-10-10 DE DE1998175039 patent/DE19875039I2/de active Active
- 1991-10-11 NO NO914004A patent/NO914004D0/no unknown
- 1991-10-11 CN CN91110816A patent/CN1046711C/zh not_active Expired - Lifetime
- 1991-10-11 CZ CS913095A patent/CZ281274B6/cs not_active IP Right Cessation
- 1991-10-11 FI FI914796A patent/FI104897B/fi not_active IP Right Cessation
- 1991-10-11 NZ NZ240194A patent/NZ240194A/en not_active IP Right Cessation
- 1991-10-11 SI SI9111647A patent/SI9111647B/sl unknown
- 1991-10-11 SK SK3095-91A patent/SK279944B6/sk not_active IP Right Cessation
- 1991-10-11 YU YU164791A patent/YU48742B/sh unknown
- 1991-10-11 PT PT99213A patent/PT99213B/pt not_active IP Right Cessation
- 1991-10-11 MX MX9101551A patent/MX9101551A/es unknown
- 1991-10-12 KR KR1019910017953A patent/KR100227716B1/ko not_active Expired - Lifetime
- 1991-10-13 IL IL99726A patent/IL99726A/en not_active IP Right Cessation
- 1991-10-13 IL IL11714796A patent/IL117147A0/xx unknown
- 1991-10-13 IL IL11714791A patent/IL117147A/xx not_active IP Right Cessation
- 1991-10-14 JP JP3331110A patent/JP2501385B2/ja not_active Expired - Lifetime
- 1991-10-16 IE IE360991A patent/IE913609A1/en active Protection Beyond IP Right Term
1993
- 1993-04-02 HR HR930751A patent/HRP930751B1/xx not_active IP Right Cessation
1995
- 1995-06-09 HU HU95P/P00178P patent/HU211294A9/hu unknown
1998
- 1998-07-17 CY CY9800016A patent/CY2094B1/xx unknown
- 1998-07-23 LV LVP-98-153A patent/LV12187B/en unknown
- 1998-09-02 LU LU90284C patent/LU90284I2/fr unknown
1999
- 1999-04-01 NL NL990009C patent/NL990009I2/nl unknown
2000
- 2000-02-07 FI FI20000250A patent/FI20000250A7/fi unknown

Also Published As

Publication number	Publication date
KR100227716B1 (ko)	1999-11-01
HUT61981A (en)	1993-03-29
CN1046711C (zh)	1999-11-24
AU8579491A (en)	1992-04-16
HRP930751A2 (en)	1995-06-30
PT99213A (pt)	1992-09-30
SI9111647B (en)	2001-06-30
FI914796L (fi)	1992-04-13
IL99726A0 (en)	1992-08-18
FI104897B (fi)	2000-04-28
CY2094B1 (en)	2002-04-05
FI20000250A7 (fi)	2000-02-07
HU913217D0 (en)	1992-01-28
EP0480717A1 (fr)	1992-04-15
LV12187A (lv)	1998-12-20
DE69129257T2 (de)	1998-11-05
YU164791A (sh)	1994-04-05
DK0480717T3 (da)	1999-02-08
IL117147A (en)	2000-10-31
KR920008006A (ko)	1992-05-27
CA2053209C (fr)	1998-12-08
FI914796A0 (fi)	1991-10-11
IE913609A1 (en)	1992-04-22
IL117147A0 (en)	1996-06-18
ES2114882T3 (es)	1998-06-16
JPH05105665A (ja)	1993-04-27
NL990009I1 (nl)	1999-06-01
PT99213B (pt)	1999-01-29
AU639610B2 (en)	1993-07-29
HRP930751B1 (en)	2000-06-30
ATE165088T1 (de)	1998-05-15
LV12187B (en)	1999-02-20
HK1027473A1 (en)	2001-01-12
NO914004D0 (no)	1991-10-11
HU222344B1 (hu)	2003-06-28
EP0480717B1 (fr)	1998-04-15
YU48742B (sh)	1999-09-27
CZ281274B6 (cs)	1996-08-14
JP2501385B2 (ja)	1996-05-29
SK279944B6 (sk)	1999-06-11
HU211294A9 (en)	1995-11-28
NL990009I2 (nl)	1999-07-01
NZ240194A (en)	1995-03-28
CN1061407A (zh)	1992-05-27
CA2053209A1 (fr)	1992-04-13
MX9101551A (es)	1992-06-05
SI9111647A (en)	1997-12-31
DE19875039I2 (de)	2003-05-22
DE69129257D1 (de)	1998-05-20
IL99726A (en)	1998-02-22
CS309591A3 (en)	1992-04-15

Publication	Publication Date	Title
FI914796A0 (fi)	1991-10-11	Omaettade hydroxialkylkinolinsyror som leukotrienantagonister.
FI944734A0 (fi)	1994-10-07	Kinoliinijohdannaiset leukotrieeniantagonisteina
FI920734A0 (fi)	1992-02-20	Ketosyror innehaollande kinoliner med leukotrienantagonisteffekt.
NO952495L (no)	1995-08-22	Diaryl-5,6-kondenserte heterosykliske syrer som leukotrienantagonister
FI914795A0 (fi)	1991-10-11	Hydroxialkylkinolinetersyror som leukotrienantagonister.
MY107767A (en)	1996-06-15	Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists